Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

52.77 USD -0.15 (-0.28%)
Official Closing Price Updated: 4:00 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Agios Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Agios Announces Closing of Oncology Business Sale to Servier
From GlobeNewswire News Releases
Agios Shareholders Approve Sale of Oncology Business to Servier
From GlobeNewswire News Releases
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
From GlobeNewswire News Releases
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
From GlobeNewswire News Releases
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
From GlobeNewswire News Releases
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases
Agios to Present at March Investor Conferences
From GlobeNewswire News Releases
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
From GlobeNewswire News Releases
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
From GlobeNewswire News Releases
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
– Supplemental New Drug Application Planned for Submission in Q1 2021 – 
From GlobeNewswire News Releases
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
From GlobeNewswire News Releases
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
From GlobeNewswire News Releases
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?
InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR. 
From PR Newswire
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
From GlobeNewswire News Releases
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
From GlobeNewswire News Releases
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
From GlobeNewswire News Releases
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
From GlobeNewswire News Releases
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
From GlobeNewswire News Releases
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
From GlobeNewswire News Releases
Agios Reports Business Highlights and Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET 
From GlobeNewswire News Releases
Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020
From GlobeNewswire News Releases
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020
From GlobeNewswire News Releases
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
From GlobeNewswire News Releases
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
From GlobeNewswire News Releases
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 
From GlobeNewswire News Releases
Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020
From GlobeNewswire News Releases
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020
CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today... 
From PR Newswire
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
From GlobeNewswire News Releases
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]